Showing results (151-160 of 164) with videos related to
Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based ApproachGuohong Han, Sarah Berhane, Hidenori Toyoda, et al.Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.Cancers|December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabYue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.European Journal of Cancer (Oxford, England : 1990)|September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyClaudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysisDan Rosmarin, Claire Palles, David Church, et al.Hepatology (Baltimore, Md.)|October 21, 2019
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol MisusersFelix Stickel, Philipp Lutz, Stephan Buch, et al.European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.Pageof 17